Search Results
Your search for 3 matches 16011 pages
Showing 1 - 50FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 13, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with the antibody-drug conjugate enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for the ...
Broad-Based Genomic Sequencing Associated With Survival Benefit Over Focused Testing for Advanced NSCLC
Patients with non–small cell lung cancer (NSCLC) who received broad-based genomic sequencing in the first-line setting showed improved survival outcomes compared with patients who received testing in the second-line setting or who received focused biomarker testing, according to study findings...
Surgical Resection Associated With Lower Mortality Than SABR in Early-Stage NSCLC
In patients with early-stage non–small cell lung cancer (NSCLC) eligible for either surgery or stereotactic ablative radiotherapy (SABR), surgical resection was associated with significantly lower 3-year all-cause mortality, according to findings from an emulated target trial reported by Kagenaar...
American Cancer Society Updates Prostate Cancer Screening Guideline
Today, the American Cancer Society (ACS) released an updated guideline for prostate cancer screening. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based screening every 2 years for average-risk men aged 50 to 69 years, with clinicians ensuring patients understand...
Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer
According to findings from a randomized phase II trial reported by Bai et al in the Journal of Clinical Oncology, treatment with the immunochemotherapy combination of the PD-1 inhibitor toripalimab and modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and fluorouracil) significantly...
Metastatic Uveal Melanoma: Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy
In the multicenter phase I/II OptimUM-01 trial, first-line treatment with the protein kinase C inhibitor darovasertib plus the MET inhibitor crizotinib demonstrated antitumor activity and a manageable safety profile in patients with previously untreated metastatic uveal melanoma, suggesting a...
KEYNOTE-867: Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
An interim analysis of the phase III KEYNOTE-867 trial published by Jabbour et al in the Journal of Clinical Oncology did not appear to support the combination of stereotactic body radiotherapy (SBRT) and pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC)....
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
In the phase III HEALER trial, first-line treatment with the HER2-targeted bispecific antibody anbenitamab plus albumin-bound docetaxel (HB1801) significantly improved progression-free survival compared with docetaxel, trastuzumab, and pertuzumab (THP) in patients with HER2-positive advanced breast ...
FDA Approves Pimicotinib for Symptomatic TGCT
On November 10, the U.S. Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity. MANEUVER Trial Efficacy was...
Beyond Chemotherapy: Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC
Updated findings from Stage 1 of the multicenter, international, two-stage phase III PRESERVE-003 trial showed that, among patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease had progressed following anti–PD-(L)1 therapy, treatment with the investigational anti–CTLA-4 ...
Preventing Africa’s Coming Cancer Crisis: The Harm Reduction Imperative
Africa is heading toward a cancer catastrophe, and the oncology community must not look away. Noncommunicable diseases already account for 37% of all deaths in the WHO African Region, up from 24% in 2000, and nearly two-thirds of these deaths occur prematurely, before 70.1,2These are not distant...
First-Line T-DXd: A Change of DESTINY for HER2-Mutant NSCLC?
In patients with advanced HER2-mutant non–small cell lung cancer (NSCLC), first-line monotherapy with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) significantly prolonged progression-free survival compared with standard-of-care chemoimmunotherapy. This was...
U.S. Food and Drug Administration Expanded Indications and Approvals in Bladder and Colorectal Cancers
Several approvals by the U.S. Food and Drug Administration (FDA) over the past month included therapeutics for patients with BCG-unresponsive non–muscle-invasive bladder cancer and locally advanced rectal cancer. Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the FDA...
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Treatment with the norepinephrine-dopamine reuptake inhibitor methylphenidate significantly reduced cancer-related fatigue in patients with hematologic malignancies compared with placebo, according to findings from the randomized, double-blind, crossover MICRO trial reported by Frederiksen et al in ...
ROSELLA Subgroup Analysis Supports Relacorilant Use in Patients Previously Treated With Taxanes
Can patients with platinum-resistant ovarian cancer treated with taxane therapy benefit from receiving relacorilant after a taxane? A new subgroup analysis from the phase III ROSELLA trial1 suggests the answer may be yes. The analysis, presented at the 2026 ASCO Annual Meeting, focused on prior...
Extended Follow-up of Nivolumab/Ipilimumab for Localized dMMR/MSI-H Gastric/GEJ Cancer
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival in patients with localized mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) gastric or gastroesophageal junction (GEJ) adenocarcinoma, based on updated...
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Chiaretti et al reported results from...
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer (NSCLC) whose disease had...
FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC
On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based...
Keeping PACE With Surgery: SBRT for Localized Prostate Cancer
An updated efficacy analysis of the international phase III PACE-A trial showed high rates of freedom from biochemical or clinical failure (BCF) with both stereotactic body radiation therapy (SBRT) and radical prostatectomy in patients with localized prostate cancer, with no statistically...
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC
In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated advanced non–small cell lung cancer (NSCLC),...
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
According to results from the phase III SAFFRON trial, the combination of osimertinib and savolitinib significantly improved progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) with MET...
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
The EGFR and HER3 bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival vs chemotherapy in heavily pretreated Chinese patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the multicenter phase III...
IOF Issues Position Statement on Bone Fragility Management for Patients With MGUS
The International Osteoporosis Foundation (IOF) Committee of Scientific Advisors (CSA) Bone and Cancer Working Group has released a position statement on bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS). The new statement provides guidance on how to...
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Wake Forest University School of Medicine Names Inaugural Chair of the Department of Cancer Medicine
Antoinette R. Tan, MD, MHSc, FACP, FASCO, has been appointed inaugural Chair of the newly formed Department of Cancer Medicine for the Charlotte, North Carolina campus of Wake Forest University School of Medicine. A clinician-scientist, Dr. Tan is a nationally recognized breast medical oncologist...
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
Patients preparing to undergo surgery for pancreatic adenocarcinoma who received stereotactic body radiation therapy (SBRT) appeared to have comparable pathologic and surgical outcomes while reporting better quality of life during treatment than those who received conventionally fractionated...
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
A hypofractionated radiotherapy regimen was noninferior to conventional radiotherapy for locoregional control among patients with high-risk breast cancer undergoing postmastectomy radiotherapy with internal mammary node irradiation, according to findings from the phase III HypoMast-IMNI trial...
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Phase III VOLGA Trial: Durvalumab/Tremelimumab/Enfortumab Vedotin Improves Outcomes in Bladder Cancer
In the phase III VOLGA trial, researchers evaluated the use of perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy....
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
Financial Navigation Program May Help Reduce Cancer-Related Financial Hardship
A financial navigation intervention was associated with significant reductions in financial toxicity among patients with cancer across rural and nonrural oncology practices, according to findings from the Lessening the Impact of Financial Toxicity (LIFT) trial reported by Wheeler et al in the...
Disitamab Vedotin Plus Tislelizumab Shows Activity in Very High–Risk Non–Muscle-Invasive Bladder Cancer
Treatment with the anti-ERBB2 antibody-drug conjugate disitamab vedotin plus the anti–PD-1 immune checkpoint inhibitor tislelizumab-jsgr showed evidence of antitumor activity in patients with transurethrally unresectable, ERBB2-positive, very high–risk non–muscle invasive bladder cancer, according...
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
In 2024, ASCO updated its guideline for the integration of palliative care in oncology, which recommends that clinicians refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams beginning early in the course of a patient’s disease ...
TALENT: Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Neoadjuvant treatment with the HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki (T-DXd), given alone, with endocrine therapy, or followed by chemotherapy, produced pathologic complete response rates (pCR) in the single digits among patients with hormone receptor (HR)-positive,...
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
Findings from a substudy of the phase III PROTEUS trial provided further support for the use of perioperative apalutamide and androgen-deprivation therapy (ADT) before and after surgery for patients with high-risk localized and locally advanced prostate cancer, according to results presented at the ...
F-SHARP Trial Evaluates Focal Salvage Brachytherapy and Genomic Risk Stratification in Recurrent Prostate Cancer
According to findings from the phase I/II F-SHARP trial reported by Solanki et al in the Journal of Clinical Oncology, dose-escalated focal salvage high–dose rate brachytherapy demonstrated favorable disease control with low rates of severe toxicity in patients with locally recurrent prostate...
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Machine learning models using routine clinical data may be able to identify individuals at higher risk of developing several common cancers, according to findings from an international study presented at the ESMO Congress 2026 (Abstract 280RO). “For selected cancers, these models could serve as a...
ESMO 2026: Sacituzumab Tirumotecan vs Physician’s Choice of Treatment in Patients With Previously Treated Endometrial Cancer
Sacituzumab tirumotecan may extend both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract...
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
The addition of consolidation radiotherapy to first-line systemic anticancer therapy resulted in better local disease control and prolonged progression-free survival compared with systemic therapy alone in patients with synchronous oligometastaic non–small cell lung cancer (NSCLC) without an...
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
Today, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor talazoparib (Talzenna) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR)...
GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer
Adults with diabetes and a history of cancer were less likely to report current use of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) than those without a cancer history, despite having higher rates of cardiovascular and kidney disease. Olinto Linares-Perdomo, PhD, and colleagues...
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer
Abiraterone acetate added to androgen-deprivation therapy and docetaxel resulted in a significant overall survival benefit compared with standard-of-care therapy alone in patients with de novo metastatic castration-sensitive prostate cancer, according to long-term findings from the phase III...
High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy May Benefit Outcomes After Surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract...
Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
